Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imilecleucel-T

Biogen Idec building

Biogen Idec says Tecfidera launch delayed in Europe

Company wants to resolve patent and regulatory data protection issues for oral MS drug

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

- PMLiVE

Merck KGaA forges clinical alliance with Quintiles

CRO becomes sole outsourcing partner for pharma company

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

- PMLiVE

Merck KGaA to meet 2014 financial targets one year early

But continued growth of Rebif under threat from new oral MS drugs

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

Biogen Idec building

Biogen wins extra patent protection for MS drug Tecfidera

Dosing patent provides exclusivity until 2028

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

Solid performance for Merck KGaA in “transformation year”

Sales and profits on track amid job cuts and restructuring

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links